BIOA
BioAge Labs, Inc.
Biotechnology
Market Cap$641M
5Y Perf.-14.3%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
BIOA vs KYMR vs VKTX vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$6.91B
5Y Perf.+78.8%
VKTX
Viking Therapeutics, Inc.
Biotechnology
Market Cap$3.66B
5Y Perf.-50.1%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.-4.5%
BIOA vs KYMR vs VKTX vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BIOA | KYMR | VKTX | IMVT |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $641M | $6.91B | $3.66B | $5.53B |
| Revenue (TTM) | $9M | $51M | $0.00 | $0.00 |
| Net Income (TTM) | $-81M | $-315M | $-472M | $-464M |
| Gross Margin | 99.2% | 33.2% | — | — |
| Operating Margin | -10.3% | -7.0% | — | — |
| Total Debt | $6M | $82M | $137K | $98K |
| Cash & Equiv. | $189M | $357M | $166M | $714M |
BIOA vs KYMR vs VKTX vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BIOA
KYMR
VKTX
IMVT
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 100 | 85.7 | -14.3% |
| Kymera Therapeutics… (KYMR) | 100 | 178.8 | +78.8% |
| Viking Therapeutics… (VKTX) | 100 | 49.9 | -50.1% |
| Immunovant, Inc. (IMVT) | 100 | 95.5 | -4.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BIOA vs KYMR vs VKTX vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BIOA and KYMR are tied at the top with 2 categories each — the right choice depends on your priorities. Kymera Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. VKTX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
BIOA
BioAge Labs, Inc.
The Growth Play
BIOA carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 66.2%
- -13.3% revenue growth vs VKTX's -270.1%
- +338.9% vs VKTX's +14.6%
Best for: growth exposure
KYMR
Kymera Therapeutics, Inc.
The Income Pick
KYMR is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- beta 1.15
- Beta 1.15, current ratio 10.47x
- Beta 1.15 vs VKTX's 1.61
- -22.3% ROA vs VKTX's -65.3%, ROIC -24.9% vs -44.4%
Best for: income & stability and defensive
VKTX
Viking Therapeutics, Inc.
The Long-Run Compounder
VKTX is the clearest fit if your priority is long-term compounding.
- 25.8% 10Y total return vs IMVT's 173.6%
- 4.7% margin vs BIOA's -9.0%
Best for: long-term compounding
IMVT
Immunovant, Inc.
The Defensive Pick
IMVT is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
Best for: sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BIOA | -13.3% revenue growth vs VKTX's -270.1% |
| Quality / Margins | VKTX | 4.7% margin vs BIOA's -9.0% |
| Stability / Safety | KYMR | Beta 1.15 vs VKTX's 1.61 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | BIOA | +338.9% vs VKTX's +14.6% |
| Efficiency (ROA) | KYMR | -22.3% ROA vs VKTX's -65.3%, ROIC -24.9% vs -44.4% |
BIOA vs KYMR vs VKTX vs IMVT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLKYMRLAGGINGIMVT
Who Leads Where
KYMR leads in 2 of 6 categories
BIOA leads 1 • VKTX leads 0 • IMVT leads 0 • 2 tied
Explore the data ↓IMVTImmunovant, Inc.
0leads
VKTXViking Therapeutics, …
0leads
BIOABioAge Labs, Inc.
1leads
KYMRKymera Therapeutics, …
2leads
6 Total Categories
CATEGORYLEADERvs BIOAvs VKTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KYMR3/5
Valuation MetricsMultiples, price ratios, and targets
BIOA2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
KYMR4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KYMR leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
KYMR and IMVT operate at a comparable scale, with $51M and $0 in trailing revenue. Profitability is closely matched — net margins range from -6.1% (KYMR) to -9.0% (BIOA).
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… | VKTXViking Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $9M | $51M | $0 | $0 |
| EBITDAEarnings before interest/tax | -$93M | -$352M | -$502M | -$487M |
| Net IncomeAfter-tax profit | -$81M | -$315M | -$472M | -$464M |
| Free Cash FlowCash after capex | -$82M | -$244M | -$340M | -$423M |
| Gross MarginGross profit ÷ Revenue | +99.2% | +33.2% | — | — |
| Operating MarginEBIT ÷ Revenue | -10.3% | -7.0% | — | — |
| Net MarginNet income ÷ Revenue | -9.0% | -6.1% | — | — |
| FCF MarginFCF ÷ Revenue | -9.2% | -4.7% | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +55.5% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +63.5% | +13.4% | -2.3% | +19.7% |
KYMR leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
BIOA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… | VKTXViking Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Market CapShares × price | $641M | $6.9B | $3.7B | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $458M | $6.6B | $3.5B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -7.96x | -22.93x | -9.90x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 71.28x | 176.26x | — | — |
| Price / BookPrice ÷ Book value/share | 2.35x | 4.52x | 5.57x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
BIOA leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
KYMR leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
KYMR delivers a -25.0% return on equity — every $100 of shareholder capital generates $-25 in annual profit, vs $-71 for VKTX. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to KYMR's 0.05x. On the Piotroski fundamental quality scale (0–9), BIOA scores 5/9 vs IMVT's 2/9, reflecting solid financial health.
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… | VKTXViking Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -27.9% | -25.0% | -71.3% | -47.1% |
| ROA (TTM)Return on assets | -25.5% | -22.3% | -65.3% | -44.1% |
| ROICReturn on invested capital | -2.1% | -24.9% | -44.4% | — |
| ROCEReturn on capital employed | -30.7% | -27.2% | -51.8% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.05x | 0.00x | 0.00x |
| Net DebtTotal debt minus cash | -$183M | -$275M | -$166M | -$714M |
| Cash & Equiv.Liquid assets | $189M | $357M | $166M | $714M |
| Total DebtShort + long-term debt | $6M | $82M | $137,000 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | -118.34x | -2119.53x | -15687.44x | — |
KYMR leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — BIOA and KYMR and VKTX each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VKTX five years ago would be worth $53,526 today (with dividends reinvested), compared to $9,732 for BIOA. Over the past 12 months, BIOA leads with a +338.9% total return vs VKTX's +14.6%. The 3-year compound annual growth rate (CAGR) favors KYMR at 45.0% vs BIOA's -0.9% — a key indicator of consistent wealth creation.
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… | VKTXViking Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +38.9% | +16.3% | -10.8% | +5.1% |
| 1-Year ReturnPast 12 months | +338.9% | +190.7% | +14.6% | +96.1% |
| 3-Year ReturnCumulative with dividends | -2.7% | +205.1% | +38.1% | +40.9% |
| 5-Year ReturnCumulative with dividends | -2.7% | +92.1% | +435.3% | +62.4% |
| 10-Year ReturnCumulative with dividends | -2.7% | +154.4% | +2576.3% | +173.6% |
| CAGR (3Y)Annualised 3-year return | -0.9% | +45.0% | +11.4% | +12.1% |
Evenly matched — BIOA and KYMR and VKTX each lead in 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KYMR and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
KYMR is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than VKTX's 1.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs VKTX's 73.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… | VKTXViking Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.41x | 1.15x | 1.61x | 1.37x |
| 52-Week HighHighest price in past year | $24.00 | $103.00 | $43.15 | $30.09 |
| 52-Week LowLowest price in past year | $3.67 | $28.06 | $22.96 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +74.3% | +82.2% | +73.2% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 55.2 | 54.1 | 47.1 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 464K | 602K | 2.3M | 1.4M |
Evenly matched — KYMR and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: BIOA as "Buy", KYMR as "Buy", VKTX as "Buy", IMVT as "Buy". Consensus price targets imply 219.0% upside for VKTX (target: $101) vs 38.3% for KYMR (target: $117).
| Metric | BIOABioAge Labs, Inc. | KYMRKymera Therapeuti… | VKTXViking Therapeuti… | IMVTImmunovant, Inc. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $45.00 | $117.06 | $100.75 | $45.50 |
| # AnalystsCovering analysts | 3 | 26 | 24 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
KYMR leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BIOA leads in 1 (Valuation Metrics). 2 tied.
Best OverallKymera Therapeutics, Inc. (KYMR)Leads 2 of 6 categories
Loading custom metrics...
BIOA vs KYMR vs VKTX vs IMVT: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is BIOA or KYMR or VKTX or IMVT a better buy right now?
Analysts rate BioAge Labs, Inc.
(BIOA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BIOA or KYMR or VKTX or IMVT?
Over the past 5 years, Viking Therapeutics, Inc.
(VKTX) delivered a total return of +435. 3%, compared to -2. 7% for BioAge Labs, Inc. (BIOA). Over 10 years, the gap is even starker: VKTX returned +25. 8% versus BIOA's -2. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BIOA or KYMR or VKTX or IMVT?
By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.
(KYMR) is the lower-risk stock at 1. 15β versus Viking Therapeutics, Inc. 's 1. 61β — meaning VKTX is approximately 40% more volatile than KYMR relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BIOA or KYMR or VKTX or IMVT?
On earnings-per-share growth, the picture is similar: BioAge Labs, Inc.
grew EPS 66. 2% year-over-year, compared to -215. 8% for Viking Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BIOA or KYMR or VKTX or IMVT?
Viking Therapeutics, Inc.
(VKTX) is the more profitable company, earning 0. 0% net margin versus -896. 1% for BioAge Labs, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VKTX leads at 0. 0% versus -1031. 5% for BIOA. At the gross margin level — before operating expenses — BIOA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BIOA or KYMR or VKTX or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BIOA or KYMR or VKTX or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Kymera Therapeutics, Inc.
(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +154. 4% 10Y return). Viking Therapeutics, Inc. (VKTX) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +154. 4%, VKTX: +25. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BIOA and KYMR and VKTX and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.